Links to NCI Materials
Links to Other Materials
Current Clinical Trials
Links to NCI Materials
Cyclooxygenase (COX) inhibitors are compounds that block cyclooxygenase enzymes, which are produced in response to inflammation and by precancerous and cancerous tissues.
Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce pain and inflammation from many medical conditions by inhibiting two different COX enzymes called COX-1 and COX-2. NSAIDs that inhibit only COX-2 enzymes were created to allow people to have relief from pain and inflammation while avoiding certain medical problems, such as stomach bleeding, that can occur when NSAIDs are taken regularly for long periods of time.
Celecoxib, Rofecoxib Associated With Risk of Cardiovascular Events
(Posted: 02/15/2005, Updated: 04/04/2006) - Participants in clinical trials who took rofecoxib (Vioxx®) and celecoxib (Celebrex®) to learn if the drugs would reduce their risk of colorectal cancer had more serious cardiovascular events, including death, than patients who took a placebo (a dummy pill), according to two studies published online ahead of print on Feb. 15, 2005, by the New England Journal of Medicine.
COX-2 Inhibitors and Cancer: Questions and Answers
(Posted: 12/17/2004, Updated: 08/30/2006) - In the Adenoma Prevention with Celecoxib (APC) Trial of more than 2,000 men and women age 30 and older, those on celecoxib were found to have 33 percent to 45 percent fewer new adenomas than those taking a placebo, however those on celecoxib had almost twice the risk of a major cardiovascular event as people on placebo.
NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial
(Posted: 12/17/2004) - The National Institutes of Health (NIH) announced today that it has suspended the use of COX-2 inhibitor celecoxib for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).
NCI-Sponsored Trials of Cyclooxygenase (COX) Inhibitors for Cancer Prevention and Treatment
(Posted: 02/27/2001, Updated: 12/17/2004) - Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. Questions and Answers
Proteomics Shows Promise in Colon Cancer Chemoprevention Study
(Posted: 04/15/2004) - Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.
 Back to Top
Links to Other Materials
FDA Issues Public Health Advisory Recommending Limited Use of Cox-2 Inhibitors
On Dec. 23, 2004, the U.S. Food and Drug Administration (FDA) issued a Public Health Advisory summarizing the agency's recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.
Back to Top
Current Clinical Trials
Cancer clinical trials involving COX inhibitors
List of open clinical trials investigating COX inhibitors in the prevention or treatment of various cancers, from NCI's clinical trials database.
Back to Top
|
